Evidence map›Paper›PMID 35817516›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2022

An In Vivo Model of Human Macrophages in Metastatic Melanoma.

Valentin Voillet, Trisha R Berger, Kelly M McKenna, Kelly G Paulson, Wei Hong Tan, Kimberly S Smythe, Daniel S Hunter, William J Valente, Stephanie Weaver, Jean S Campbell and 7 more

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Humanized mouse models for immuno-oncology research.Nature reviews. Clinical oncology · 2023
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Valentin VoilletVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0002-5751-3881
Trisha R BergerProgram in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0003-3439-3239
Kelly M McKennaProgram in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
Kelly G PaulsonProgram in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
Wei Hong TanProgram in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
Kimberly S SmytheProgram in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0002-2329-8298
Daniel S HunterProgram in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
William J ValenteGraduate Program in Molecular and Cellular Biology, University of Washington, Seattle, WA.
Stephanie WeaverExperimental Histopathology, Fred Hutchinson Cancer Center, Seattle, WA.
Jean S CampbellProgram in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0002-9187-2204
Teresa S KimDepartment of Surgery, University of Washington, Seattle, WA.ORCID 0000-0002-6040-7748
David R ByrdDepartment of Surgery, University of Washington, Seattle, WA.
Jason H BielasDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA.
Robert H PierceProgram in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
Aude G ChapuisProgram in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
Raphaël GottardoVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.
Anthony RongvauxProgram in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA; rongvaux@fredhutch.org.ORCID 0000-0001-7142-6533

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
Interdisciplinary Tranining in Cancer ResearchT32CA080416 · NCI · UNIVERSITY OF WASHINGTON · PI STODDARD, BARRY L. · 1998 to 2023
$9.7M
Targeting macrophages in metastatic cancerR01CA234720 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI RONGVAUX, ANTHONY · 2019 to 2023
$2.2M
NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA234720NCI NIH HHS T32 CA080416
6 · The paper itself

Abstract

Despite recent therapeutic progress, advanced melanoma remains lethal for many patients. The composition of the immune tumor microenvironment (TME) has decisive impacts on therapy response and disease outcome, and high-dimensional analyses of patient samples reveal the heterogeneity of the immune TME. Macrophages infiltrate TMEs and generally associate with tumor progression, but the underlying mechanisms are incompletely understood. Because experimental systems are needed to elucidate the functional properties of these cells, we developed a humanized mouse model reconstituted with human immune cells and human melanoma. We used two strains of recipient mice, supporting or not supporting the development of human myeloid cells. We found that human myeloid cells favored metastatic spread of the primary tumor, thereby recapitulating the cancer-supportive role of macrophages. We next analyzed the transcriptome of human immune cells infiltrating tumors versus other tissues. This analysis identified a cluster of myeloid cells present in the TME, but not in other tissues, which do not correspond to canonical M2 cells. The transcriptome of these cells is characterized by high expression of glycolytic enzymes and multiple chemokines and by low expression of gene sets associated with inflammation and adaptive immunity. Compared with humanized mouse results, we found transcriptionally similar myeloid cells in patient-derived samples of melanoma and other cancer types. The humanized mouse model described here thus complements patient sample analyses, enabling further elucidation of fundamental principles in melanoma biology beyond M1/M2 macrophage polarization. The model can also support the development and evaluation of candidate antitumor therapies.

Indexed as

MacrophagesMelanomaAnimalsCell Line, TumorDisease Models, AnimalHumansMacrophage ActivationMiceTumor Microenvironment

Identifiers

PMID35817516
PMCPMC9377377

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.